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Synopsis  
This prospective national surveillance study identifies the incidence (0.21 per 100,000 in age 
16), aetiology, management and visual outcome in children with choroidal 
neovascularization. Visual prognosis was poor irrespective of CNV location and use of anti-
VEGF therapy. 
 Abstract  
Background/Aims: To determine the United Kingdom (UK) incidence, demographics, 
aetiology, management and visual outcome for children developing choroidal 
neovascularization (CNV). 
Methods: A prospective population-based observational study of routine practice via 
theBritish Ophthalmological Surveillance Unit (BOSU) between January 2012 to December 
2013 with subsequent1 year follow-up in children under 16 years old with newly diagnosed 
CNV. 
Results: Twenty-seven children with CNV were reported. The UK estimated annual 
incidence for those aged 16 and under was 0.21 per 100,000 (95% CI: 0.133-0.299). Mean 
age 11.1 years (SD 3.9, range 4-16). Fourteen were female. Seventy-seven per cent (22 
patients) were Caucasian British. Twenty-three children (85%) had unilateral disease. The 
most common aetiology included inflammatory retinochoroidopathy (n=9), optic disc 
abnormalities (n=9), and idiopathic (n=5).  Optical coherence tomography (OCT) was 
performed in all cases and fundus fluorescein angiography (FFA) in 61%. Management 
included observation only (n=10), anti-vascular endothelial growth factor (VEGF) injection 
of bevacizumab (n=14) or ranibizumab (n=2) or both (n=1), and additional use of oral (n=1) 
and local (periocular n=2 and intravitreal n=2) steroids in five children with inflammatory 
retinochoroidopathy.  The mean number of anti-VEGF injections was 2±1, with eight patients 
receiving only one injection. The mean (SD) best corrected visual acuity (BCVA) in 
LogMAR was 0.91 (0.53) at presentation and 0.74(0.53) at 1 year follow-up (p=0.09).  
Conclusion: This is the first population-based prospective study of CNV in children. This is 
a rare disorder with a poor visual prognosis irrespective of CNV location and the use of anti-
VEGF therapy.
Introduction 
In the paediatric population, choroidal neovascularisation (CNV)has been reported in 
association with infection, inflammation, optic disc anomalies, retinal dystrophies, trauma 
and may also be idiopathic[1].Although causes of CNV have been reviewed before[1 2], the 
incidence of CNV in children is unknown; there have been no reported prospective 
epidemiological studies. The management of CNV in the paediatric setting is challenging, 
there are a number of options such as observation, photodynamic therapy (PDT), laser 
photocoagulation, sub-macular surgery and anti-vascular endothelial growth factor (VEGF) 
agents, all yielding variable visualoutcomes.[3-6]Theuseofanti-
VEGFagentsremainscontroversialassuppressingthephysiological role of VEGF may have 
deleterious effects in children.[3]This British Ophthalmological Surveillance Unit (BOSU) 
study is the first prospective epidemiological study providing national data on the incidence, 
aetiology, treatment and visual outcome of CNV in a paediatric population. 
Methods 
This was a prospective population-based study performed in association with the BOSU 
monthly reporting system.[7 8] All ophthalmologists with clinical autonomy (consultant and 
associate specialist grade, however we did not ascertain their subspecialty) in the United 
Kingdom (UK) receive a monthly reporting card with definitions of the conditions currently 
under surveillance and they indicate how many new cases are seen each month. For the 24-
month study period between January 2012 to December 2013, ophthalmologists were asked 
to report any case of new CNV in patients ≤16 years old. Every ophthalmologist who notified 
a patient to BOSU was sent an initial questionnaire requesting information regarding 
demographics, aetiology, presenting features and first-line management. A one year follow-
up questionnaire was also sent to ascertain subsequent management and visual outcome. 
Ophthalmologists who did not return a questionnaire were sent a reminder letter. 
Questionnaires are available as supplementary materials. The protocol of this study adhered 
to the provisions of the Declaration of Helsinki and was approved by the local ethics 
committee of Moorfields Eye Hospital and BOSU.  
Statistical analyses 
All statistical analyses were performed using the Statistical Package for the Social Sciences 
(version 21.0; SPSS Inc., an IBM Company, Chicago, IL). Continuous variables (BCVA 
baseline, BCVA follow up, and age are presented as the mean (standard deviation, SD) after 
assessing for normality by inspection of histograms. Categorical variables were compared 
using Chi squared test. Differences between BCVA baseline and BCVA follow-up were 
compared using the paired t-test. For comparison of BCVA at baseline and follow-up 
amongst the different CNV locations and management groups, the ANOVA test was used. A 
P value <0.05 was considered statistically significant.  Details of all affected eyes (n=31) 
were reported in the table 1, however, information of only 27 eyes were used for the 
statistical analysis. Bilateral cases were not simultaneous and, in the statistical analysis, we 
included only the eye that was treated or the most recent diagnosed. In addition, only 16 
unaffected eyes were reported on by the respondents. As this is a rare condition, numbers are 
small and so the power of this study to detect associations was limited. 
 
Results 
Reports to BOSU leading to estimates of the UK incidence of CNV 
During the study period, the BOSU used a reporting base of 1245 ophthalmologists. Between 
January 2012 to December 2013 inclusive, BOSU received 39 reports of patients with CNV 
(card return rate 75%), of these only 32 incident questionnaires were returned; one patient 
was older than 16, thus excluded; and there were three duplicates and one triplicate (this 
constituted the same patient referred to other ophthalmologists within the UK for further 
management, hence the patient was over-reported), each one was only counted once to ensure 
accurate incidence calculations but with full collection of management data. This left 27 
children with the accurately reported target disorder. After 12 months, 96.2% of reporting 
ophthalmologists returned the 1year follow‐up questionnaire providing follow up data on 26 
out of 27cases.The mid-year population for 2013was estimated to be approximately64.1 
million, with a denominator of 12.8 million for children aged 16 and under (the UK Statistic 
Authority website: http://www.statistics.gov.uk/). The UK estimated annual incidence for 
those aged 16 and under was 0.21 per 100,000 (95% CI: 0.133-0.299). 
Patient characteristics and presenting details 
Based on the 27 patients initially reported, themean age at presentation was11.1 years (SD 
3.9, range 4-16). Fourteen were female. Seventy-seven percent (22 patients) were Caucasian 
British, 2 Caucasian non-British, 1 Indian, 1 African and 1 mixed Caucasian and Black 
Caribbean. Main sources of referral are reported in Fig. 1A. Five patients (19%) were 
asymptomatic at diagnosis, identified through regular hospital surveillance of their pre-
existing ophthalmic condition (n=3) and routine vision check with optometrists (n=2). 
Median duration of symptoms (reduced vision, positive scotoma) was 31 days (range 1-252). 
The clinical findings are summarized in Table 1.  
 
Unilateral presentation was most common, found in 23 children (85%).  Four patients had 
bilateral presentation; 2 patients with inflammatory retinochoroidopathy; 1 with Best disease 
macular dystrophy; and 1 with bilateral chorioretinal coloboma.  In patients with bilateral 
disease, the localization of the CNV was the same in both eyes. Nearly half (48%) of cases 
(n=13) had a subfoveal CNV, 7 patients (26%) had peripapillary CNV and in the remaining 7 
(26%) it extended from the peripapillary region to the macula.  
 
The most common aetiology included inflammatory retinochoroidopathy (n=9), of which five 
cases were secondary to multifocal choroiditis), optic disc abnormalities (n=9), of which five 
cases were secondary to optic disc drusen), Best disease (n=2), high myopia (n=1), idiopathic 
(n=5) and one associated with laser toy injury (Fig 1B). Twenty-two patients did not have 
any systemic diseases, however, four patients had a medical history of epilepsy, vitiligo, 
ventricular septal defect or sarcoidosis.All patients had an OCT, FFA was performed in 16 
patients (61%), three cases had indocyanine green angiography (8%). Ultrasound, 
electrodiagnostic testing and autofluorescence was performed together in one case. 
 
Management included observation only (n=10), anti-VEGF intravitreal injection of 
bevacizumab (n=14) or ranibizumab (n=2), and both in one case.  Eight patients received 
only one injection, four patients two injections, two patients three injections and two patients 
(one with optic disc drusen and the other with toxocara uveitis) had four injections. 
Additional steroid treatment was reported in five patients with inflammation; 2 patients 
received a biodegradable intravitreal implant of 700 g of preservative-free dexamethasone 
(Ozurdex®; Allergan, Inc, Irvine, CA, USA); 2 patients had periocular triamcinolone 
acetonide (4 mg) injection; and one patient was treated with oral prednisolone.  
 
A total of twenty-one patients did not have any complications following treatment. There 
were no complications amongst those who received anti-VEGF injections. Two patients with 
inflammatory CNV treated with anti-VEGF and steroid intravitreal implant reported raised 
intra ocular pressure (patient 16 and 27), and cataract formation (patient 16). For 3 cases, this 
information was missing and one respondent failed to send back the 1 year follow-up 
questionnaire. 
 
The mean (SD) spherical equivalent refraction at presentation in the affected eye was 0.30 
(2.55), range −9.25 to 5.00. The presenting mean (SD) BCVA in LogMAR of affected eyes 
was 0.91 (0.53) and at 1 year was 0.74 (0.53), there was a mild improvement in overall vision 
compared to the presenting BCVA, although not significant (p=0.09). The distribution of 
BCVA from baseline to the end of follow-up was similar across the different locations of 
CNV (ANOVA p=0.46 and p=0.09 respectively). In the macula only group, BCVA baseline 
in LogMAR was 0.98 (0.61) and at one-year follow-up 0.72 (0.61) (p=0.14); in the 
peripapillary extending to macula region, BCVA baseline was 0.85 (0.42) and at one-year 
follow-up 0.64 (0.37) (p=0.12); and in the peripapillary area only BCVA baseline was 0.99 
(0.38) and at one-year follow-up 1.0 (0.42) LogMAR (p=0.77, Fig 1C). Overall, during the 
follow-up, five patients (19%) maintained the same BCVA, 15 (58%) reported a slight 
improvement and six patients (23%) a reduction. One patient did not have visual acuity 
follow-up. There was no statistical significant difference in the BCVA at the end of follow-up 
between the different management groups (ANOVA=0.43). Patients treated with anti-VEGF 
had a baseline BCVA in LogMAR of 1.0 (0.58) and one-year follow-up of 0.70 (0.56) 
(p=0.14). Patients treated with a combination of anti-VEGF and steroids had a baseline 
BCVA in LogMAR of 0.76 (0.47) and one-year follow-up of 0.69 (0.85) (p=0.82). Patients 
without any treatment had a baseline BCVA of 1.0 (0.14) and one-year follow-up of 
0.86(0.38) (p=0.13). One patient was treated with immunosuppressants only and her worse 
eye deteriorated from 0.30 LogMAR to 1.0 LogMAR at one-year follow-up (Fig. 1D). No 
statistical significance difference was identified between different treatments at each CNV 
location. (Supplementary Fig 2). No difference amongst gender was identified for the visual 
acuity outcome (chi-square=0.1, p=0.92) and no significant correlation was identified 
between the age at diagnosis and the BCVA at the end of follow-up (r=-0.11, p=0.58). 
Presenting mean (SD) BCVA in LogMAR of unaffected eyes (n=16) was 0.06 (0.17) and at 
one-year was 0.10 (0.22), there was no statistical significant difference (p=0.90) in unaffected 
eyes over this follow-up period. 
 
Discussion 
 
This is the first population-based prospective study of CNV in children. The disorder is rare 
with an annual incidence in the UK for those aged 16 and under of 0.21 per 100,000. Two 
retrospective studies of CNV in children younger than 18 years[2 9]reported opposing gender 
preponderance with Barth et al.[9] reporting a strong female predominance (80%), in contrast 
to  Rishi et al.[2]who described a higher male preponderance (63%).This result may be due to 
the different ethnic background and access to healthcare facilities. In our study, no gender 
preference was identified and the visual acuity outcome was the same in both groups. CNV in 
the paediatric age group is generally seen in older children[2 9] although it has been reported 
in a 4 month old[10] with congenital toxoplasmosis, and a 3 year-old with North Carolina 
macular dystrophy.[11]In our study, the youngest presentation was seen in two female4 year-
olds with optic disc anomalies but the majority of cases were in older children with a mean 
age at presentation of 11 years. The most common aetiologies were inflammatory disease, 
particularly multifocal choroiditis and optic disc anomalies, which is in concordance with 
Rishi and colleagues. Whereas Barth et al.[9]reported choroidal osteoma followed by 
hereditary macular dystrophy as the most common causes. Both studies reported that most 
CNV was subfoveal. There was an equal divide with half our patients developing subfoveal 
CNV with the other half having extrafoveal CNV extending from or solely involving in the 
peripapillary region. 
 
Before the advent of anti-VEGF therapy most cases of CNV in children were managed by 
observation but there were a few reports of the outcome of sub-macular surgery [4 12]or 
PDT.[6 13] The lack of calcification, thickening of Bruch’s membrane and a solitary 
ingrowth site were better candidates for surgery.[14]The visual outcomes of 35 children with 
CNV that underwent surgery revealed ninety percent had a preoperative visual acuity of 0.6 
LogMAR or worse and seventy-five per cent gained two or more Snellen lines in visual 
acuity post-surgery.[4 5]Mateo and colleagues[12]reported 2 cases of sub-macular surgery 
for CNV in children associated with optic disc drusen; a 16-year-old boy whose visual acuity 
improved from 1.0LogMAR to 0.09 LogMAR at 26 months follow-up, and a 12 year-old boy 
with an improvement from 0.40to 0.09 LogMAR at 24 months follow-up without any 
evidence of recurrence. However, a 9-year-old girl with bilateral peripapillary CNV with 
subfoveal extension in the left eye secondary to optic disc drusen underwent sub-macular 
surgery and her visual acuity worsened from 0.05 to 0.3 in the left eye but did not change 
from 0.3 in the right eye during the 6-month post-operative period.[15]The results of PDT in 
paediatric CNV are also encouraging.[6 13]Twelve patients with age range4 -15 years 
underwent PDT for CNV associated with toxoplasma, Best disease or idiopathic causes. 
Follow-up ranged from 7-77 months, and PDT was able to reduce leakage in 10 out of 12 
cases with an improvement in visual acuity in nine cases. The treatment was safe and 
effective but there was an intrinsic risk of the regressed membrane leaving a scar causing a 
reduction in visual acuity over time. 
 
The most common treatment for CNV in children reported in our survey was intravitreal anti-
VEGF injection, and steroids in inflammatory cases. There were no cases of PDT, focal laser 
and sub-macular surgery reported. There are no randomized prospective clinical trials that 
assess the interventions for CNV in childhood, but anti-VEGF treatment seems to have 
become the preferred first line approach. Several case reports reported in the literature 
describe the treatment of CNV associated with optic disc drusen with anti-VEGF agents.[16 
17].Anti-VEGF agents do not appear to be associated with any ocular toxicity in the 
developing eye in humans and this is supported from experimental studies in 
animals.[18]However, some authors considered treatment with bevacizumab in infants with 
retinopathy of prematurity (ROP) a significant risk for retinal function and the development 
of the retinal vasculature.[19] A more serious concern is whether leakage of anti-VEGF 
agents into the circulation after intravitreal injection may interact with VEGF receptors in 
other tissues such as the developing brain. A recent observational study found that infants 
with ROP who were treated with bevacizumab had greater risk of neurodevelopmental 
disabilities, such as motor delay, compared with those who had laser (but the group of infants 
who received bevacizumab also a more severe form of ROP).[20]There are no clinical studies 
that are large enough to evaluate the systemic effects of intravitreal anti-VEGF drugs in 
children. A multicentre retrospective study reported no ocular or systemic side effects 
relating to anti-VEGF treatment for CNV, Coats disease, familial exudative vitreoretinopathy 
and cystoid macular oedema at 1 year follow-up[3] in 90 children, in concordance with no 
reported side effects in our survey. Avery et al[21] suggested that ranibizumab may be more 
appropriate for children due to its shorter serum half-life. Regarding the dosage, some studies 
use a standard adult dose of 1.25 mg/0.05ml of bevacizumab or 0.5 mg/0.05ml of 
ranibizumab[22] as there is little difference in ocular volume between older children and 
adult eyes, preterm infants with a smaller ocular size require a lower dosage.[23]The number 
of injections required to control the disease was lower compared to adults[3], and this was 
supported by the favourable course of CNV in younger subjects reported by Spaide et al[24], 
attributed to the better health of the RPE pump.[2] 
 
In our cohort, steroid use was required in combination with anti-VEGF injections in five 
children affected by inflammatory retinochoroidopathy. The anti-angiogenic approach for 
inflammatory CNV has already been described and identified to be effective when the 
inflammation is controlled.[25] 
 
Observation remains an important management option. Previous papers report spontaneous 
regression in 58%[26]and 41.7%[2] of eyes. A characteristic finding that may be predictive 
of regression is a pigmented ring or encapsulation around the lesion.[27]In our cohort, 
amongst the observation group, 7 out of 10 cases had a spontaneous improvement in visual 
acuity, although overall, the visual outcome remained poor. Subfoveal location of the CNV 
complex, exudative detachment, subretinal pigment epithelial hemorrhage and cystoid 
degenerative changes of the neurosensory retina may strongly compromise the visual 
outcome.[27] Ninety percent of patients in a case series with initial visual acuity of less than 
1.0 LogMAR remained unchanged.[26] In our sample, almost half of the patients did not 
report any significant subjective changes in visual acuity during the follow-up, but 33% 
showed a slight objective improvement.  
 
A potential limitation of this study could be the under-ascertainment of CNV from referring 
UK ophthalmologists. The high card return rate and previous evaluation of the methodology 
suggest good levels of compliance, but the incidence of CNV in children in this study is a 
minimum estimation. The study was not designed to evaluate different methods of treatment 
and can only give a snapshot of treatment modalities used in current UK practice and the 
general visual outcomes. 
 
In conclusion, inflammatory retinochoroidopathies and optic disc abnormalities are the 
commonest associations with CNV in the paediatric population. Most affected eyes will have 
a subfoveal CNV location. However, we found no evidence of a relationship between CNV 
location and baseline VA. Eyes treated with anti-VEGF with a macula or peripapillary CNV 
extending to macula resulted in a slight improvement in VA; but the observation-only group 
reported a similar VA improvement. Patients with peripapillary CNV did not show any 
improvement using anti-VEGF or steroids whereas a slight improvement was found if they 
were observed. It should be noted, however, that because this is a rare condition, numbers are 
small and thus power to detect differences is low.  Ocular co-morbidities play an important 
role in deciding the choice of treatment and they have an important impact on the visual 
outcome. No particular treatment has been validated, but laser coagulation, photodynamic 
therapy, and submacular surgery are not being employed in the UK for this condition. 
 
 
 
Legends: 
Fig 1(A) Pie chart showing the main source of referral for paediatric CNV in the UK. (B) Pie 
chart reporting the aetiologies associated with CNV. (C) Bar graph showing the distribution 
of BCVA in LogMAR at baseline and at the end of follow-up according to the CNV location 
and (D) within the different management groups. Mean (SD) BCVA value is reported. No 
statistical significant difference was found across the different locations of CNV nor 
management groups. * indicates the patient without follow-up. 
 
Supplementary figure 1. Bar graph showing the distribution of BCVA in LogMAR at 
baseline and at the end of follow-up according to the CNV locations and treatments. No 
statistical significant difference was found across the different locations of CNV nor 
management groups. * indicates the patient without follow-up. 
Table 1 Clinical data and treatment details of 27 children with choroidal neovascularization 
Patient 
N. 
 
Gender 
Age 
Years 
BCVA 
Baseline 
LogMAR 
BCVA 
Follow-up 
LogMAR 
CNV   
location 
 
Ocular comorbidity 
 
Treatment 
No. of injections 
(or dose) 
Unilateral cases 
1 M 14 1.77 1.47 Macula only Laser toy injury Observation  
2 M 14 0.73 0.60 Macula only Multifocal choroiditis Bevacizumab/Ranibizumab 1/2 
3 F 6 0.96 0.52 Peripapillary 
extending to 
macula 
 
Optic disc drusen 
 
Observation 
 
4 F 16 2.00 2.00 Macula only Idiopathic Bevacizumab 2 
5 M 10 1.30 1.20 Macula only Idiopathic Observation  
6 F 12 1.30 1.10 Peripapillary 
extending to 
macula 
Multifocalchoroiditis  
Ranibizumab 
 
1 
7 F 13 1.30 0.00 Macula only High myopia Bevacizumab 2 
8 M 15 0.44 0.02 Macula only Multifocal choroiditis Bevacizumab/Prednisolone 1/(20mg) 
9 M 15 0.32 0.12 Macula only Best disease Observation  
10 F 13 0.60 0.77 Macula only Toxoplasmosis Bevacizumab 1 
11 F 4 0.77 0.17 Peripapillary 
extending to 
macula 
 
Optic disc coloboma 
 
Bevacizumab 
 
1 
12 M 12 0.74 0.80 Peripapillary 
only 
Congenital optic disc 
harmatoma 
Bevacizumab 1 
13 M 15 0.00 0.30 Peripapillary 
extending to 
macula 
 
Optic disc drusen 
 
Bevacizumab 
 
4 
14 M 7 1.00 1.00 Macula only Multifocal choroiditis Bevacizumab 1 
15 F 9 0.30 0.17 Macula only Panuveitis Bevacizumab/ periocular 
triamcinolone 
1 
16 M 15 1.00 0.70 Peripapillary 
extending to 
macula 
Toxocara uveitis Ranibizumab/triamcinolone/ 
dexamethasone intravitreal implant 
 
4/1/1 
17 M 11 1.15 1.15 Peripapillary 
extending to 
macula 
 
Idiopathic 
 
Observation 
 
18 M 8 0.60 1.00 Peripapillary 
only 
Optic nerve hypoplasia Observation  
19 M 16 1.60 0.87 Peripapillary 
only 
Optic disc drusen Observation  
20 F 18 0.90 0.90 Peripapillary 
only 
Idiopathic Observation  
21 F 4 0.80 0.80 Peripapillary 
only 
Optic disc drusen Bevacizumab 2 
22 F 13 1.90 0.17 Macula only Idiopathic Bevacizumab 1 
23 F 13 0.00 ---------- Peripapillary 
only 
Optic disc drusen Bevacizumab 3 
Bilateral cases 
24 M 8 RE 0.58 
LE  0.86 
0.38 
0.84 
Macula only Best disease Observation  
25 F 16 RE 0.77 
LE 1.00 
0.60 
1.00 
Peripapillary 
extending to 
macula 
Bilateral retinal coloboma 
and left iris coloboma 
Observation  
26 F 5 RE 0.30 
LE 0.30 
1.00 
0.00 
Macula only Vogt-Koyanagi- Harada 
syndrome 
Oral steroids and methotrexate  
27 F 6 RE 1.30 
LE 0.17 
1.90 
0.39 
Peripapillary 
only 
Multifocal choroiditis Bevacizumab/dexamethasone 
intravitreal implant 
RE 1 
LE 1 
 
F= Female, M=Male, BCVA= Best corrected Visual Acuity, CNV= choroidal neovascularization, RE=Right eye, LE=Left    
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